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Abstract: Amyotrophic lateral sclerosis (ALS) is the most common neurodegenerative disorder of
motor neurons in adults, with a median survival of 3–5 years after appearance of symptoms, and
with no curative treatment currently available. Frontotemporal dementia (FTD) is also an adult-
onset neurodegenerative disease, displaying not only clinical overlap with ALS, but also significant
similarities at genetic and pathologic levels. Apart from the progressive loss of neurons and the
accumulation of protein inclusions in certain cells and tissues, both disorders are characterized by
chronic inflammation mediated by activated microglia and astrocytes, with an early and critical
impact of neurodegeneration along the disease course. Despite the progress made in the last two
decades in our knowledge around these disorders, the underlying molecular mechanisms of such
non-cell autonomous neuronal loss still need to be clarified. In particular, immune signaling kinases
are currently thought to have a key role in determining the neuroprotective or neurodegenerative
nature of the central and peripheral immune states in health and disease. This review provides a
comprehensive and updated view of the proposed mechanisms, therapeutic potential, and ongoing
clinical trials of immune-related kinases that have been linked to ALS and/or FTD, by covering the
more established TBK1, RIPK1/3, RACK I, and EPHA4 kinases, as well as other emerging players in
ALS and FTD immune signaling.
Keywords: amyotrophic lateral sclerosis (ALS); frontotemporal dementia (FTD); kinase; neuroinflammation;
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1. Pathological and Molecular Features of ALS and FTD
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease
characterized by the selective and progressive degeneration and loss of motor neurons in
spinal cord, brain and brainstem, controlling voluntary muscles [1]. With an incidence of
1–2:100,000, ALS is currently incurable and ultimately fatal, and once symptoms arise it is
typically lethal within the next 5 years [2,3]. There is substantial heterogeneity in clinical
manifestations, and most cases are considered sporadic as they occur without a known
cause or a known family history. However, even though clinically indistinguishable from
sporadic ALS, about 5–10% of cases are caused by genetic mutations and referred to as
familiar ALS [3]. The pathophysiological processes underlying ALS are currently believed
to be multifactorial, reflecting a complex interaction between genetic and environmental
factors [4]. Multiple mutations have been located within four major ALS-associated genes,
namely C9orf72, SOD1, TARDBP (encoding the TDP-43 protein) and FUS, in addition to at
least 40 other genes [5].
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A key pathological hallmark of ALS is the accumulation of misfolded TDP-43 and,
in some cases, SOD1 or FUS proteins. These aberrant protein aggregates are currently
thought to cause neuronal damage due to a loss of the native protein’s function and/or by
a gain of toxic function exerted through various possible mechanisms [6]. Indeed, different
pathogenic processes are supported by the accumulated data from in vitro, ex vivo and
in vivo studies: mitochondrial dysfunction, reactive oxygen species (ROS) associated ox-
idative stress, dysregulated proteostasis, impaired autophagy, activation of ER-induced
cell death, impaired stress granule formation, and altered RNA metabolism and/or
processing [3,6]. Apart from these general cytotoxic mechanisms, neuroinflammation—a
non-cell autonomous mechanism of neurodegeneration and neuronal loss—is currently
considered a key player in the onset and progression of ALS and other neurodegenerative
diseases [7].
Frontotemporal degeneration (FTD) is a fatal type of dementia characterized by at-
rophy of the frontal and temporal brain lobes, and is associated with behavioral and
personality changes [3,8]. Mutations in three genes, namely MAPT (encoding tau), GRN
and C9orf72, agglutinate the majority of familial FTD cases. Remarkably, approximately
15% of patients display motor symptoms and up to 50% of ALS patients develop frontal
lobe dysfunction that may be associated with cognitive and behavioral impairment [9].
Even though ALS and FTD are thought to be at different ends of a pathological spectrum
and have traditionally been considered two independent clinical entities, many patients
present both conditions (ALS-FTD) [3,8]. Moreover, it is increasingly recognized that they
partially overlap in their clinical manifestations and display certain common genetic ori-
gins and pathophysiological mechanisms [8,10]. For example, a number of genes have
been identified as causes or risk factors of both ALS and FTD, such as TARDBP, C9orf72,
VCP, UBQLN2, SQSTM1 and TBK1, among others. Interestingly, several of these genes are
implicated in specific molecular pathways, namely RNA regulation, autophagy, vesicle
and inclusion formation, and immunity [5,10]. Furthermore, the accumulation of ubiquiti-
nated protein aggregates in degenerating neurons and other CNS cell types, particularly
cytoplasmic TDP-43 species and C9orf72 dipeptide-repeat protein (DPR) aggregates, are
also a common denominator in tissue samples from ALS and FTD patients, both familial
and sporadic [10].
Another common feature of ALS and FTD, which is shared with virtually all neurode-
generative diseases, is the build-up of sustained neuroinflammation in affected regions
of the CNS [3]. Peripheral immune cells, particularly T cells and other non-CNS-residing
immune cells, are known to contribute to disease progression in some neurodegenerative
diseases, and we have recently found that disease-like protein aggregates are capable of
eliciting responses both from innate and peripheral immune cells [11,12]. However, the
involvement of peripheral immunity in ALS or FTD is still poorly understood, and the
bulk of evidence points to activation of innate immune signaling pathways in microglia
and astrocytes resident in the CNS as a very early event in the pathological process [3,13].
In ALS, even though both neuroinflammation and systemic inflammation are consis-
tently present in ALS patients—and, according to animal models, since the early stages of
disease—whether these phenomena are an outcome of disease, or instead play a contribu-
tory or even causative role in pathogenesis, is still under debate. Importantly, activated mi-
croglia and astrocytes in animal models of ALS at the initial stages show anti-inflammatory
and neuroprotective profiles, whereas in the late stages they display proinflammatory and
neurodegenerative features [4], supporting the notion that neuroinflammation has a central
role in the onset, exacerbation, progression, and stages of the disease [3,13].
2. Importance of Immune-Related Kinases in ALS and FTD
Remarkably, the accumulated evidence for ALS indicates that, regardless of the molec-
ular mechanisms of injury operating on neuronal cells, different cellular pathways that may
be triggered converge, leading to a neurodegenerative inflammatory cascade [4]. At the
same time, cascades of different processes could result in motor neuron death, including
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cell-autonomous and non-cell autonomous mechanisms, regardless of the exact cause of
each ALS case [3]. Either way, neuroinflammation is currently recognized as a major con-
tributor to neurodegeneration in ALS and other neurodegenerative disorders [4,7]. One of
the mechanisms that could have a major impact in driving uncontrolled neuroinflammation
and, ultimately, neuronal cell death in ALS and FTD, is the dysfunctional regulation of
certain kinases involved in immune signaling (Figure 1).
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 3 of 16 
 
 
including cell-autonomous and non-cell autonomous mechanisms, regardless of the exact 
cause of each ALS case [3]. Either way, neuroinflammation is currently recognized as a 
major contributor to neurodegeneration in ALS and other neurodegenerative disorders 
[4,7]. One of the mechanisms that could have a major impact in driving uncontrolled neu-
roinflammation and, ultimately, neuronal cell death in ALS and FTD, is the dysfunctional 
regulation of certain kinases involved in immune signaling (Figure 1). 
 
Figure 1. Immune-related kinases involved in ALS/FTD physiopathology. Schematic overview of 
immune-related kinases that have been implicated in in ALS or FTD, based on in vitro, ex vivo, in 
vivo or genetic studies. (Top): Signaling kinases known to display immune-related functions (ovals) 
and the identified signaling pathways in which they participate (hexagons) from various inflamma-
tion-based disease models. Specific kinase inhibitors (rectangles) that have been used to modulate 
some of these kinases are also shown. (Bottom): Different cell types located within the CNS or in the 
periphery, through which immune-related kinases may play a role in ALS/FTD pathophysiological 
processes. 
Figure 1. Immune-related kinases involved in ALS/FTD physiopathology. Schematic overview of
immune-related kinases that have been implicated in in ALS or FTD, based on in vitro, ex vivo,
in vivo or genetic studies. (Top): Signaling kinases known to display immune-related functions
(ovals) and the identified signaling pathways in which they participate (hexagons) fro various
inflammation-based dis ase models. Specific kinase inhibitors (rect ngles) that have been used
to modulate some of these kinases are also shown. (Bottom): Different cell types located within
the CNS or in the periphery, through which immune-related kinases may play a role in ALS/FTD
pathophysiological processes.
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Indeed, apart from the various studies revealing the dysregulated expression of
inflammatory-related genes and proteins in ALS patient tissues [3], and the implication
of several signaling kinases in the pathophysiology of ALS [14], the recent discovery of
TBK1 as an ALS-causing gene [15,16] suggests a direct link between neuroinflammation
and signaling kinases in ALS and other related diseases.
3. Kinases and Immune Signaling in ALS and FTD Pathogenesis
3.1. TBK1 (TANK-Binding Kinase 1)
TBK1, a pleiotropic serine/threonine kinase, is involved in the regulation of selective
autophagy and inflammatory responses via type-I interferon (IFN) signaling [17]. Two
independent human sequencing studies were the first to link different mutations in the
TBK1 gene to ALS [15,16]. At the same time, three pioneering studies originally connected
TBK1 mutations with FTD [15,18,19]. Thus far, several studies have identified a large
number of TBK1 variations dispersed throughout the protein sequence to be a major cause
of both familial and sporadic, ALS, FTD and ALS-FTD [17]. Some of them have been shown
to cause a loss of kinase function [20], which resulted in rather evident abnormalities in-
cluding dendritic swelling, abnormally shaped astrocytes, and p62-and ubiquitin-positive
aggregates in the cerebellum, as observed in TBK1-KO mice [21]. However, the majority
of ALS-associated TBK1 variants are missense mutations and their contribution to ALS
pathogenesis still needs to be elucidated [17]. Interestingly, post-mortem brain analyses
from ALS/FTD patients carrying TBK1 mutations have revealed cytoplasmic or perin-
uclear TDP-43-positive and p62-positive inclusions [16,19,22]. These findings may not
seem surprising as TBK1 has been implicated in autophagy [17], while an ALS-associated
TBK1 variant was unable to promote TDP-43 autophagic degradation dependent on p62
phosphorylation [23].
TBK1 is highly expressed in neurons among other cell types, and its expression and
activation has also been observed in microglia [17,24]. TBK1 participates in immune signal-
ing pathways by acting as an essential component of the type I IFN response (reviewed
in [25]). Indeed, during the antiviral innate immune response, TBK1—which belongs to the
IKK-kinase family—becomes activated and phosphorylates the downstream transcription
factors IRF3 and IRF7, which dimerize, translocate to the nucleus, and initiate gene expres-
sion of IFNα and IFNβ cytokines. Recent studies in vitro have shown that ALS-associated
TBK1 variants retain different levels of kinase activity and display a range of signaling
efficiencies leading to IRF3 phosphorylation [26]. In addition, results from another in vitro
study indicate that, whereas wild-type TBK1 promotes the NF-kB pathway and suppresses
Nrf2 signaling, the ALS-associated p.G175S kinase-deficient, TBK1 mutant does not [23].
In addition, an essential role of TBK1 in inhibiting RIPK1-dependent apoptosis and
inflammation, via phosphorylation of a particular Thr residue downstream of TNF recep-
tor 1 (TNFR1), was demonstrated [27]. Remarkably, the study further showed that, in
TBK1 deficient mice, the reduced myeloid expression of TAK1—an endogenous RIPK1
inhibitor—promoted the key ALS/FTD phenotype hallmarks, including microgliosis,
TDP-43 aggregation, neuronal loss, and behavioral deficits [27]. Moreover, global heterozy-
gous deletion of TBK1 modelling the TBK1 loss-of-function mutations found in ALS/FTD
in humans, was seen to exert a dual and stage-specific effect in SOD1G93A mice, by initially
preponing muscular denervation and clinical onset, but reducing microglial neuroinflam-
mation and decelerating disease progression at later stages [28]. Interestingly, a recent
study based both on general knockout and motor-neuron-selective deletion of TBK1 in
SOD1G93A mice proposed that the observed reduction in gliosis in spinal cord is actually a
non-cell autonomous result of selective loss of TBK1 in motor neurons [29], whereas de-
creased TBK1 kinase activity in all cells reduces the phosphorylation of IRF3 in SOD1G93A
mice, resulting in suppression of IFN-stimulated genes in glial cells and leading to slowing
of neurodegeneration [29].
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3.2. RIPK1 (Receptor-Interacting Kinase 1)
RIPK1 is a death-domain containing Ser/Thr kinase which functions as a key regulator
of cell death—including necroptosis and RIPK1-dependent apoptosis—and inflammatory
responses, and has been implicated in a number of CNS diseases [30,31]. In particular,
RIPK1 kinase activity has also been shown to promote inflammatory responses under
caspase-deficient conditions [32]. Even though there is no causal evidence linking RIPK1
mutations to ALS, this gene was shown to mediate axonal degeneration by promoting
inflammation and subsequent oligodendrocytes necroptosis in ALS [33], and a proinflam-
matory role of RIPK1 kinase activity in the CNS in association with TBK1 was demonstrated,
as mentioned above [27]. Importantly, a recent study based on single-cell RNA sequencing
has identified a RIPK1-regulated inflammatory microglial (RRIM) subset in early-stage
SOD1G93A mice [34]. Differently from Disease-Associated Microglia (DAM), the RRIM state
was characterized by up-regulation of classic proinflammatory pathways, and was found
to peak at an earlier time point in the ALS model, compared to the DAM phenotype [34].
3.3. Eph Receptors (Ephrin Receptor Family)
The Eph receptors of tyrosine kinases, in combination with their ephrin ligands, con-
stitute a bidirectional signaling mechanism known to mediate neuron–glia crosstalk and
to undergo expression alterations following neuronal injury and neurodegeneration [35].
A link for these receptors with ALS was originally established when Epha4 was identi-
fied as a modulator of motor neuron degeneration and disease progression in fish and
mouse disease models [36]. In addition to its role in the regulation of axonal growth and
remodeling, Epha4 was found to function as a mediator of inflammation in spinal cord and
traumatic brain injuries [37,38], potentially via the mTOR, p-Akt and NF-kB pathways [38].
Epha4-specific nanobodies [39], an EphA4 receptor soluble antagonist [40] and se-
lective Epha4-binding compounds [41], were developed to treat ALS and delivered en-
couraging results in delaying disease progression in the SOD1G93A model. However,
pre-symptomatic lowering of Epha4 levels in ALS mice, ubiquitously or specifically in CNS,
by genetic abrogation or by administration of antisense oligonucleotides (ASOs) did not
show a significant improvement in motor function, disease onset, or survival [42,43]. This
probably reflects a highly complex mechanism of Epha4, or the ephrin system in general, in
ALS pathogenic processes [14]. On the other hand, a study based on the SOD1G93A mouse
model and on human iPSC-derived astrocytes provided evidence that EphB1-mediated
signaling can induce astrocytic STAT3 activation, invoking a protective transcriptional
profile [44]. Importantly, the authors also demonstrated that such EphB1-induced pathways
are disrupted in ALS, resulting in impaired astrocyte activation and failure in response to
neuronal injury [44].
3.4. RACK1 (Receptor of Activated Protein C Kinase 1)
RACK1, an intracellular protein receptor for protein kinase C (PKC), has been asso-
ciated with ALS as it was found to co-localize with cytoplasmic TDP-43 in spinal motor
neurons in patients [45]. Additionally, the same study revealed that RACK1—which func-
tions as a ribosomal scaffold for several proteins—mediates TDP-43 binding to ribosomes
and polysomes and recruitment of TDP-43 to stress granules [45]. Interestingly, RACK1 was
also shown to modulate microglial resistance against LPS-induced inflammatory injury [46].
Moreover, non-ribosomal RACK1 was recently shown to mediate the activation of the
inflammasome system—intracellular multiprotein complexes belonging to innate immu-
nity that enable a rapid and powerful inflammatory response against multiple stimuli—by
serving as a key NLRP3 interacting protein that promotes the NLRP3 active conformation
and inflammasome assembly [47].
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3.5. AMPK (AMP-Activated Protein Kinase) and LRRK2 (Leucine-Rich-Repeat Kinase 2), New
Immune Signaling Kinases in ALS/FTD
Certain kinases with known functions in immune signaling have been recently in-
volved in ALS or FTD based on studies using preclinical models and samples from patients.
AMPK, a Ser/Thr kinase which is ubiquitously expressed in mammalian cells, including
neurons and immune cells in the brain, is one such case. Intriguingly, studies have reported
enhanced AMPK activation in spinal cord from SOD1G93A mice and spinal motor neurons
from ALS patients, but diminished AMPK activation in spinal cord and brain from TDP-43
mutant mice (reviewed in [48]). AMPK functions as a master energy sensor for regulating
cellular metabolism and maintaining energy homeostasis, and metabolic and energetic
dysfunction are well-documented features in ALS [48]. In addition, AMPK plays a promi-
nent role—shared with the mTOR complex 1 (mTORC1) kinase—in initiation of autophagy
by activating the ULK1 complex. Indeed, there is mounting evidence that the autophagy-
lysosome pathway is compromised, via multiple proposed mechanisms, of C9orf72 and
TDP-43 ALS-FTD models (reviewed in [49,50]). Importantly, accumulating data based on
cell culture studies and rodent animal models, also implicate AMPK in the regulation of
neuroinflammation by promoting the shift of microglial activation from pro-inflammatory
to anti-inflammatory states, via inhibition of NF-kB signaling and enhancement of the Nrf2
pathway (reviewed in [51]).
A recent genome-wide association study assessing the genetic overlap between FTD-
related disorders and inflammatory diseases identified LRRK2 and TBK-binding protein 1
(TBKBP1) as FTD association candidates [52]. Two other genetic studies had previously pro-
posed an association between LRRK2 mutations—well known to be a cause of Parkinson’s
and Crohn’s diseases—and FTD [53,54] and a recent NGS-bioinformatics-based analysis of
a sporadic FTD cohort, further supported this association [55]. LRRK2 is a multi-domain
protein bearing GTPase and Ser/Thr kinase catalytic activities, as well as diverse protein
interacting regions. LRRK2 is highly expressed in immune cells and has been widely
implicated in diverse immune-related pathways in peripheral and central immune cells,
including microglia (reviewed in [56,57]). In particular, results from studies based on
inflammatory and neurodegenerative disease models indicate that LRRK2 promotes neu-
roinflammation by a number of mechanisms that may be dysregulated in microglia and
other immune cells, including the activation of MAPK-JNK signaling [58–60], suppression
of the NFAT cytokine-regulating transcription factor [61,62], dectin-1-mediated C-type
lectin signaling [63], phosphorylation and activation of NLRC4-inflammasome [64], and
promoting the NF-κB pathway by controlling the NF-κB p50 inhibitory signal and by
negatively regulating the activation of protein kinase A (PKA), an inhibitor of NF-κB
signaling [65,66].
Apart from its prominent role in immune signaling, accumulating evidence also
supports a role of LRRK2 in autophagy and the lysosome pathway in immune cells, partic-
ularly in the context of inflammatory responses in monocytes, astrocytes and macrophages
(reviewed in [57]). Interestingly, LRRK2 was found to interact with RIPK1 and to en-
able the formation of a distinct and essential ubiquitinated RIPK1 intermediate along the
RIPK1-dependent apoptosis pathway [67,68]. However, possibly owing to the very recent
connection established between LRRK2 and ALS/FTD, no study has thus far interrogated
the possible role of LRRK2 in ALS/FTD immune dysregulation.
4. Other Emerging Signaling Kinases in ALS/FTD
Protein kinase RNA-activated (PKR) is a central intracellular stress sensor that can
be activated by a variety of stimuli, particularly dsRNA, leading to autophosphorylation
and resulting in proinflammatory responses via NF-kB, p38 and c-Jun N-terminal kinase
(JNK) signaling, as part of the classical innate immunity to viral infection [69]. Repetitive
element (RE) transcripts, which are prone to form dsRNA species, were found at higher
levels in ALS patients’ brains [70], while mechanistic relationships between dysregulated
TDP-43 function or C9orf72-repeat expansion, and increased transposable RE transcripts,
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have been suggested [70,71]. Interestingly, a recent study based on astrocyte primary
cell cultures demonstrated that knocked-down TDP-43 leads to higher RE transcript and
dsRNA levels [72]. Moreover, results from double knockdown assays support a mechanism
by which PKR—which had been detected at higher levels in spinal cord samples from ALS
patients [73]—mediates astrocyte activation and the ‘reactive’ proinflammatory phenotype
resulting from TDP-43 downregulation [72]. On the other hand, a recent study demon-
strated that PKR highly regulates repeat-associated non-AUG (RAN) translation [74], an
aberrant mechanism reported in various ‘repeat expansion diseases’ such as C9orf72 ALS
and FTD [75–77]. Furthermore, the study showed that repeat expansion RNAs, including
ALS/FTD ‘C9 repeats, increase active/phosphorylated PKR (p-PKR) levels in vitro and
in vivo in mice, while higher p-PKR levels were detected in hippocampal tissue from
C9orf72 ALS patients [74].
Recently, as a result of our study of the inflammatory response in microglial cells ex-
posed to TDP-43 aggregates, we identified MAPK/MAK/MRK overlapping kinase (MOK)
as a protein that strongly interacts with cytoplasmic TDP-43 aggregates [78]. Moreover,
MOK was found to alter its phosphorylation state in critical residue Tyr161, both in primary
microglia and organotypic spinal cord cultures [78]. MOK is an atypical Ser/Thr signaling
kinase that belongs to the MAPK superfamily [79], and which has been predicted to play
an important role in diverse physiological and pathological processes [80].
5. Immune Kinase Modulation for ALS and FTD in Disease Managing and in
Clinical Trials
Thus far, only two drugs have been approved for therapeutic treatment of ALS: Riluzole,
by both the FDA and EMA agencies and also approved for FTD [81], and Edaravone,
authorized more recently by the FDA [82]. Riluzole—via poorly understood mechanisms—
displays activity against glutamatergic excitotoxic and non-excitotoxic oxidative neuronal
injury, and has been used extensively in the clinic for 25 years, prolonging median survival
by only two to three months in ALS patients [83]. Interestingly, Riluzole was later found
to be a direct inhibitor of protein kinase C (PKC) [84], a kinase family well-known to play
a key role in the development and effector functions of major immune cell types, and
implicated in both innate and adaptive responses [85]. Because of the limited therapeutic
power of these drugs, there is a clear need to identify novel molecular targets that could be
potentially modulated in a specific and effective manner for the treatment of ALS and FTD.
Currently, a few immune kinase inhibitors are being tested in clinical trials (Table 1).
Table 1. Clinical trials based on immune kinase inhibitors currently underway for ALS or FTD treatment.
Drug Kinase Target Study Phase Year Launched 1 Code Number Disease
Masitinib Tyrosine kinase receptors III 2020–2022 NCT03127267 ALS
Fasudil ROCK II 2020 NCT03792490 ALS








(recruiting) 2021 NCT02862210 FTD
1 Phase starting year (according to latest update).
5.1. Masitinib: A Receptor Tyr Kinase Inhibitor
Masitinib is a selective tyrosine kinase inhibitor [86] with neuroprotective and anti-
inflammatory capability demonstrated in a number of preclinical studies [86–89]. Masitinib
was shown to target a limited number of kinases known to be involved in cancer and
inflammatory diseases, at safe doses [86] and was later demonstrated to reduce neuroin-
flammation by controlling microgliosis and counteracting mast cell degranulation [87,90].
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The compound is thought to exert neuroprotection via its immunomodulatory properties
through targeting microglia, macrophages, mast cells and neutrophils, and implicating
both central and peripheral nervous systems [91,92]. Importantly, oral administration of
this compound showed a 25% delay in disease progression in a recent phase II/III clinical
as an add-on therapy to Riluzole in ALS patients [92]. Masitinib has now entered a phase III
clinical trial, which is currently ongoing.
5.2. Fasudil: A ROCK1/2 (Rho-Kinase 1/2) Inhibitor
ROCK is a Ser/Thr kinase that is expressed as two homologues, ROCK1 and ROCK2,
and whose activity is modulated by Ras-superfamily upstream regulators, namely the
Rho GTPases RhoA and RhoC. ROCK phosphorylates a number of targets involved in
regulation of a variety of crucial cellular processes including cell motility, apoptosis and
cell survival in different cell types, including neurons and microglia (reviewed in [93,94]).
In the latter, the ROCK pathway contributes to defining microglial phenotype by regulating
microglial migration, phagocytosis and the release of inflammatory cytokines [95,96]. While
abnormally high levels of ROCK were detected in skeletal muscle biopsies from sporadic
ALS patients [97], pre-symptomatic administration of Fasudil to SOD1G93A mice improved
survival and motor performance [98].
At a pathological level, motor neuron degeneration was shown to be partially sup-
pressed and neuromuscular junction remodeling, enhanced. Interestingly, while the num-
ber of astroglial cells was reduced, Fasudil treatment led to increased microglia numbers
and shifted activation profile from the neurotoxic M1 to the protective M2 phenotype [98],
in line with previous in vitro and in vivo studies in other pathophysiological contexts [99,100].
Furthermore, oral administration of Fasudil to symptomatic SOD1G93A mice resulted in
improved motor behavior in males [101]. Still, there is currently no sufficient evidence
for a direct immune-based mechanism of ROCK in ALS pathology. Instead, recent pre-
clinical studies with Fasudil in SOD1 mice provide evidence for participation of ROCK
dysregulation in ALS pathogenesis caused by imbalance of pro-survival Rac/pro-apoptotic
Rho-ROCK signaling in motor neurons [102] and by impaired ROCK-signaling controlling
axonal regeneration [103]. This compound, applied intravenously, is currently undergoing
a phase II clinical trial.
5.3. DNL Compounds: RIPK1 Inhibitors
Based on the functions recently described for RIPK1 kinase in regulating inflammation
and necroptotic cell death, specific small-molecule inhibitors have been developed as
treatment candidates for chronic inflammatory diseases [104,105]. In 2017 and shortly after
its initiation, a phase Ia clinical study of DNL104—a brain-penetrant RIPK1 inhibitor—was
discontinued due to liver toxicity effects. A selective and brain-permeable RIPK1 inhibitor
DNL747 was designed subsequently and announced in 2020 for a phase Ib/II clinical trial in
ALS [105], but the study was paused when it was concluded that higher doses—which were
likely to cause adverse effects according to studies with cynomolgus monkeys [106]—would
be needed to improve efficacy. Importantly, the alternative compound DNL788, which
appears to display a superior profile and is expected to avoid the side effects seen at high
doses for DNL747, is due to enter phase II clinical testing in 2022 [107].
5.4. Lithium Carbonate: A GSK3α/β (Glycogen Synthase Kinase 3) Inhibitor
GSK3 has been found to be a point of convergence of many signaling pathways and
to regulate, in a highly complex manner, many cellular functions through its capacity
to phosphorylate a wide variety of substrates [108]. Remarkably, studies in the last two
decades have revealed that GSK3 participates in several signaling pathways and is an
important regulator of innate immune responses by enabling cytokine production upon
TLR stimulation in both the periphery and the CNS, and of adaptive immunity by modu-
lating the specificity and clonal expansion of T and B cells [108,109]. Based on its role as a
major tau kinase, inhibition of GSK3 with lithium—the gold-standard treatment for bipolar
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disorder—has been tested for the treatment of tauopathies, including AD and subtypes of
FTD. In cultured cells and in transgenic mice, lithium-induced GSK3β inhibition was seen
to reduce tau phosphorylation, increase the binding of tau to microtubules and promote
microtubule assembly [110,111]. Interestingly, Li+ has been shown to rescue autophagy
failure observed in ALS/FTD and, in recent years, lithium administration has been assessed
in clinical trials in ALS, thus far with debatable results [112]. Of note, a phase II clinical
trial with low-dose lithium (against placebo) for the treatment of behavioral symptoms in
FTD is currently ongoing [113].
6. Immune Kinase Modulators in the Pipeline towards ALS/FTD Therapy
6.1. Metformin: A PKR Inhibitor
Based on results obtained in vitro which showed that metformin—a widely prescribed
drug for type 2 diabetes treatment, known to activate the AMPK pathway [114]—inhibits
PKR and reduces the levels of several RAN proteins in mammalian cells, the effect of this
drug was tested in vivo by using C9-BAC mice, a C9orf72-based pre-clinical model of
ALS [74]. Administration of metformin at the pre-symptomatic stage resulted in lowered
DPR aggregates and p-PKR levels. Moreover, as opposed to a previous study using the
SOD1G93A ALS model [115], treatment of C9-BAC mice with the drug up until the advanced
stage led to substantially reduced astrogliosis in the motor cortex, decreased motor neuron
degeneration in the spinal cord, and improved locomotive and behavioral parameters,
compared to non-treated animals [74].
6.2. C4: An Epha4 Ligand
Following encouraging results by a study showing significant delay in disease pro-
gression in the SOD1G93A mouse model [41], the brain-penetrant, high-selectivity and
high-affinity small molecule EPHa4 ligand 123C4—presumably a receptor agonist—is cur-
rently being evaluated in preclinical models for ALS by Iron Horse Therapeutics (San Diego,
CA, USA) [88].
7. Concluding Remarks
In the last few years, it has become increasingly evident that ALS and FTD share
clinical, genetic, and mechanistic cues, a feature which may provide hints on their elusive
pathogenic mechanisms. A number of signaling pathways and their executing kinases—
many of which are known to mediate immune functions, particularly, inflammatory
responses—have been recently linked to ALS or FTD. Some of them have been associ-
ated genetically to these disorders, such as TBK1; others, including e.g., RIPK1, do not
seem to have a direct genetic link with these disorders, but are known to participate in
their pathogenic mechanisms.
An increasing number of studies in recent years point to a mechanistic link between
mitochondrial and autophagy disruption in neurodegenerative disorders, including ALS
and FTD. Interestingly, neuroinflammation, which has emerged as a principal determinant
of neurodegeneration in these disorders, has been recently linked to both dysregulated
processes [17,116], adding a possible new layer of complexity to the neuroinflammation–
neurodegeneration interaction network.
Based on the growing body of knowledge generated in the last two decades in ALS
and especially in AD and other related neurodegenerative diseases, a number of immune
kinases have emerged as highly promising molecular targets for therapeutic intervention.
Indeed, a short list of immune kinase inhibitors are currently being tested in clinical trials or
are undergoing pre-clinical studies. Surely, due to a virtual lack of an effective therapy for
ALS and FTD patients, further investigation towards the identification of novel therapeutic
targets is warranted.
From the reviewed data, it seems obvious that, despite the progress made over the last
two decades, substantial effort must still be made in the field to improve our understanding
of the intricate mechanisms underlying ALS and FTD pathogenesis, including immune
Int. J. Mol. Sci. 2021, 22, 13280 10 of 15
signaling pathways, which would prompt the identification of novel kinase therapeutic
targets. In addition to a better understanding of these highly complex pathogenic processes,
better stratification of patients would improve the design and outcome of clinical trials
and, thereby, boost therapeutic development.
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